New £26 million pharmaceutical manufacturing unit opens

Torbay Pharmaceuticals, part of Torbay and South Devon NHS Foundation Trust, held an official opening on Monday to mark the completion of the 78,000 square foot unit, which boasts the latest technology and equipment required to provide a modern pharmaceutical facility.

Prior to the build of the new manufacturing unit, Torbay Pharmaceuticals’ units were spread over four different sites. Work began to prepare the site back in March 2013 and since the buildings physical completion back in December 2014, rigorous testing has been taking place.

The unit develops and makes a wide range of medicinal products for UK NHS hospitals and healthcare organisations across the world, with the proceeds generated ploughed back in to local health care in Torbay and South Devon.

Sir Richard Ibbotson, chairman of Torbay and South Devon NHS Foundation Trust, said: “We are incredibly proud of Torbay Pharmaceuticals and all that they have achieved over the years. Not only have they created a range of highly skilled career opportunities, but they generate income which directly supports the health and care of local people. This is a first-rate example of what innovation in the NHS can contribute to local communities.

“These fabulous new facilities offer a modern, class-leading environment which will enable Torbay Pharmaceuticals to further grow and flourish. I, on behalf of the Trust Board, cannot thank everyone enough for their hard work in seeing this superb project come to fruition.”

Emma Rooth, managing director of Torbay Pharmaceuticals, added: “Since the establishment of the original pharmaceutical department at Torbay Hospital back in the 1970s, we have grown from strength to strength to meet not only our local population’s needs, but also the needs of the wider NHS and health care providers globally.

“The official opening of our new class-leading sterile product facility is a very exciting time for Torbay Pharmaceuticals. By strengthening our production capabilities and ensuring the delivery of high quality products for our patients through this investment, we have created the platform upon which we can achieve significant growth for the organisation, its people and the region.”

To find out more, click here.